Cowen Prime Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Cowen Prime Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,000	Closed	-$87K	–	229
2016 Q3	$87K	Hold	1,000	–	–	0.04%	140
2016 Q2	$86K	Sell	1,000 -1,000	-50%	-$86.4K	0.04%	125
2016 Q1	$159K	Hold	2,000	–	–	0.07%	104
2015 Q4	$252K	Buy	+2,000	New	+$241K	0.11%	85
2015 Q3	–	Sell	-2,000	Closed	-$247K	–	273
2015 Q2	$247K	Buy	2,000 +1,000	+100%	+$126K	0.1%	95
2015 Q1	$118K	Buy	+1,000	New	+$120K	0.05%	140

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cowen Prime Advisors's VRTX Position: Q4 2016 in Review

Cowen Prime Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 1,000 shares — an estimated $87K sold.

Cowen Prime Advisors first reported a position in VRTX in Q1 2015 and held it in 6 quarters. The position peaked at $252K in Q4 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

Cowen Prime Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Cowen Prime Advisors sold 1,000 Vertex Pharmaceuticals shares in Q4 2016, an estimated $87K.
Cowen Prime Advisors first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Cowen Prime Advisors's Vertex Pharmaceuticals position peaked at $252K in Q4 2015.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Cowen Prime Advisors's 13F filing for Q4 2016, filed 9 Feb 2017.